Why Is LIVANOVA PLC (LIVN) Stock Up Today?

LIVN shares surged 17.88% to close at $94.19, driven by a strong third-quarter earnings report and raised full-year guidance. The medical technology company exceeded expectations, prompting several analysts to upgrade their price targets.

What Happened

LivaNova reported third-quarter results that signaled strong growth ahead. The company raised its full-year 2026 adjusted EPS guidance from $4.30 to $4.40 to a range of $4.40 to $4.50, compared to an estimate of $4.37. Revenue guidance was also increased from $1.499 billion to $1.513 billion to a range of $1.513 billion to $1.527 billion, against an estimate of $1.522 billion. LivaNova further forecast 2026 revenue growth of 9% to 10%.

Analyst reactions were swift and positive. Jefferies raised its price target to $120 from $100 on the strength of the guidance. Mizuho also raised its target, citing Essenz placements. Needham maintained its Buy rating while lifting its price target to $112 from $93.

What The Data Shows

The stock closed at $94.19, well above its 52-week range of $48.82 to $85.76. On November 4, 2026, the stock printed a fresh 52-week high. Over the last eight sessions, the stock moved up 16.8% from $80.62 to $94.19. Fundamentals show a market cap of $4.4 billion, a P/E ratio of 23.5, and revenue growth of 12.4% on a trailing twelve-month basis. The net margin stands at 12.8%, and the beta is 0.92.

Recent insider activity shows four sells totaling $800,000 in the last 90 days, with no buys. The most recent sale was recorded on September 14, 2026. Specific transactions include sales by directors Francesco Bianchi and Brooke Story in August and September 2026.

What To Watch

Investors will monitor how the stock sustains its momentum following the guidance raise. With the stock now trading significantly above its previous 52-week high, the market will look for continued execution on the 9% to 10% revenue growth forecast for 2026.